CoreCap Advisors’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.89M Buy
46,624
+5,039
+12% +$664K 0.17% 132
2026
Q1
$5.8M Buy
41,585
+40,084
+2,670% +$5.61M 0.2% 107
2025
Q4
$184K Sell
1,501
-514
-26% -$62.5K 0.01% 824
2025
Q3
$224K Sell
2,015
-5,286
-72% -$601K 0.01% 766
2025
Q2
$810K Buy
7,301
+753
+11% +$80.1K 0.03% 394
2025
Q1
$734K Sell
6,548
-18,120
-73% -$1.87M 0.03% 401
2024
Q4
$2.28M Buy
24,668
+23,638
+2,295% +$2.13M 0.1% 194
2024
Q3
$86.4K Buy
+1,030
New +$78.6K ﹤0.01% 978
2024
Q2
Sell
-1,880
Closed -$138K 1977
2024
Q1
$138K Buy
+1,880
New +$145K 0.01% 737
2023
Q3
Sell
-6,861
Closed -$529K 577
2023
Q2
$529K Buy
+6,861
New +$547K 0.04% 336
2022
Q4
$186K Sell
2,165
-23,311
-92% -$1.85M 0.01% 554
2022
Q3
$1.57M Buy
25,476
+24,144
+1,813% +$1.52M 0.13% 141
2022
Q2
$82K Buy
+1,332
New +$82.5K 0.01% 755
2022
Q1
Sell
-892
Closed -$65K 1132
2021
Q4
$65K Buy
+892
New +$61.4K ﹤0.01% 909

Other funds holding GILD

CoreCap Advisors's GILD Position: Q2 2026 in Review

CoreCap Advisors increased its Gilead Sciences (GILD) stake by 12% in Q2 2026, buying an estimated $664K and bringing the position to 46,624 shares worth $5.89M. The position accounts for 0.17% of the portfolio, ranked #132.

CoreCap Advisors first reported a position in GILD in Q4 2021 and has held it in 14 quarters since. 407 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • CoreCap Advisors held 46,624 shares of Gilead Sciences worth $5.89M as of Q2 2026.
  • CoreCap Advisors bought 5,039 Gilead Sciences shares in Q2 2026, an estimated $664K.
  • Gilead Sciences made up 0.17% of CoreCap Advisors's portfolio in Q2 2026, its #132 holding.
  • CoreCap Advisors first reported a position in Gilead Sciences in Q4 2021 and has held it in 14 quarters since.
  • 407 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.